Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide combination regimens for soft-tissue sarcoma

R Stuart-Harris1, D Dalley, D R Bell

  • 1Department of Medical Oncology and Palliative Care, Westmead Hospital, Sydney, New South Wales, Australia.

Cancer Chemotherapy and Pharmacology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Traditional and modern medicine: morbidity of paediatric forearm fractures in Sierra Leone.

The Journal of hand surgery, European volume·2012
Same author

Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2012
Same author

'Front and back' flaps for multiple dorsal and palmar digital skin loss.

The Journal of hand surgery, European volume·2010
Same author

Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand.

Internal medicine journal·2009
Same author

Development and evaluation of a test for tuberculosis in live European badgers (Meles meles) based on measurement of gamma interferon mRNA by real-time PCR.

Journal of clinical microbiology·2007
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

Two ifosfamide-based chemotherapy trials for advanced soft-tissue sarcoma showed limited efficacy. Combination regimens did not outperform single-agent therapies, indicating a need for novel treatment approaches.

Area of Science:

  • Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • Advanced soft-tissue sarcoma presents a significant treatment challenge.
  • Ifosfamide and doxorubicin are commonly used agents in sarcoma chemotherapy.
  • Evaluating combination chemotherapy regimens is crucial for improving patient outcomes.

Purpose of the Study:

  • To assess the efficacy and toxicity of two ifosfamide-based combination chemotherapy regimens in patients with advanced soft-tissue sarcoma.
  • To compare the effectiveness of these combination regimens against single-agent therapies.

Main Methods:

  • Two distinct clinical trials were conducted.
  • Study 1: 50 patients received ifosfamide, mesna, and doxorubicin every 3 weeks.
  • Study 2: 51 patients received ifosfamide, mesna, and etoposide over 3 days.

Related Experiment Videos

Main Results:

  • Study 1 yielded an objective response rate of 22% (3 CRs, 8 PRs) with a median survival of 12 months.
  • Study 2 achieved an objective response rate of 12% (1 CR, 5 PRs) with a median survival of 7.4 months.
  • Common toxicities included leukopenia, nausea, vomiting, and alopecia in both studies.

Conclusions:

  • Neither ifosfamide-based combination regimen demonstrated superior efficacy compared to single-agent ifosfamide or doxorubicin for advanced soft-tissue sarcoma.
  • Current combination chemotherapy strategies require re-evaluation.
  • Novel therapeutic approaches are necessary to improve treatment outcomes for this patient population.